{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:35:15Z","timestamp":1792596915406,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA269607"],"award-info":[{"award-number":["RO1CA269607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14731-4","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:39:45Z","timestamp":1758807585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel HP\u03b2CD-Cu(DDC)2 delivery system in patient derived orthotopic xenograft targeting MGMT-mediated temozolomide resistance in glioblastoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Hamid","family":"Suhail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ataur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Kumar","family":"Yadab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunalee","family":"Gonawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"deCarvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Ewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meser M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"1","key":"14731_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00289-022-04085-6","volume":"80","author":"N Tarannum","year":"2023","unstructured":"Tarannum, N., Kumar, D., Surya, S. G. & Dramou, P. Point-of-care detection assay based on biomarker-imprinted polymer for different cancers: a state-of-the-art review. Polym. Bull. 80 (1), 1\u201346 (2023).","journal-title":"Polym. Bull."},{"key":"14731_CR2","doi-asserted-by":"crossref","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro-oncology 24 (Supplement_5), v1\u2013v95 (2022).","DOI":"10.1093\/neuonc\/noac202"},{"key":"14731_CR3","doi-asserted-by":"crossref","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018. Neuro-oncology 24 (Supplement_3), iii1\u2013iii38 (2022).","DOI":"10.1093\/neuonc\/noac161"},{"issue":"10","key":"14731_CR4","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans, S. et al. Epidemiology of glioblastoma multiforme\u2013literature review. Cancers 14 (10), 2412 (2022).","journal-title":"Cancers"},{"key":"14731_CR5","doi-asserted-by":"publisher","first-page":"100872","DOI":"10.1016\/j.neo.2022.100872","volume":"36","author":"WN Al-Holou","year":"2023","unstructured":"Al-Holou, W. N. et al. Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma. Neoplasia 36, 100872 (2023).","journal-title":"Neoplasia"},{"issue":"5","key":"14731_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359 (5), 492\u2013507 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"14731_CR7","first-page":"333","volume":"92","author":"F Dhermain","year":"2005","unstructured":"Dhermain, F. et al. Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma. Bull. Cancer. 92 (4), 333\u2013342 (2005).","journal-title":"Bull. Cancer"},{"issue":"10","key":"14731_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene Silencing and benefit from Temozolomide in glioblastoma. N Engl. J. Med. 352 (10), 997\u20131003 (2005).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"14731_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11910-014-0507-z","volume":"15","author":"JW Taylor","year":"2015","unstructured":"Taylor, J. W. & Schiff, D. Treatment considerations for MGMT-unmethylated glioblastoma. Curr. Neurol. Neurosci. Rep. 15 (1), 507 (2015).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"2","key":"14731_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3892\/ijo.2024.5668","volume":"65","author":"JH Sherman","year":"2024","unstructured":"Sherman, J. H., Bobak, A., Arsiwala, T., Lockman, P. & Aulakh, S. Targeting drug resistance in glioblastoma. Int. J. Oncol. 65 (2), 80 (2024).","journal-title":"Int. J. Oncol."},{"issue":"7","key":"14731_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.neo.2014.06.003","volume":"16","author":"GJ Baker","year":"2014","unstructured":"Baker, G. J. et al. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 16 (7), 543\u2013561 (2014).","journal-title":"Neoplasia"},{"key":"14731_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mrrev.2016.05.005","volume":"769","author":"H Erasimus","year":"2016","unstructured":"Erasimus, H., Gobin, M., Niclou, S. & Van Dyck, E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat. Research\/Reviews Mutat. Res. 769, 19\u201335 (2016).","journal-title":"Mutat. Research\/Reviews Mutat. Res."},{"issue":"10","key":"14731_CR13","doi-asserted-by":"publisher","first-page":"10383","DOI":"10.1021\/nn503735w","volume":"8","author":"ZR Stephen","year":"2014","unstructured":"Stephen, Z. R. et al. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6-benzylguanine to brain tumors. ACS Nano. 8 (10), 10383\u201310395 (2014).","journal-title":"ACS Nano"},{"key":"14731_CR14","unstructured":"Huang, J. et al. A phase 1\/2 study of disulfiram and copper with concurrent radiation therapy and temozolomide for patients with newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. (2024)."},{"key":"14731_CR15","doi-asserted-by":"crossref","unstructured":"Poole, A., Lun, X., Robbins, S. M. & Senger, D. L. Overcoming therapeutic resistance in glioblastoma: Moving beyond the sole targeting of the glioma cells. In Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance. 91\u2013118. (Elsevier, 2021).","DOI":"10.1016\/B978-0-12-821310-0.00009-7"},{"issue":"15","key":"14731_CR16","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1158\/1078-0432.CCR-15-1798","volume":"22","author":"X Lun","year":"2016","unstructured":"Lun, X. et al. Disulfiram when combined with copper enhances the therapeutic effects of Temozolomide for the treatment of glioblastoma. Clin. Cancer Res. 22 (15), 3860\u20133875 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"14731_CR17","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.3390\/nu16213741","volume":"16","author":"N Or\u0161oli\u0107","year":"2024","unstructured":"Or\u0161oli\u0107, N. & Jembrek, M. J. Potential strategies for overcoming drug resistance pathways using propolis and its polyphenolic\/flavonoid compounds in combination with chemotherapy and radiotherapy. Nutrients 16 (21), 3741 (2024).","journal-title":"Nutrients"},{"key":"14731_CR18","doi-asserted-by":"publisher","first-page":"103449","DOI":"10.1016\/j.dnarep.2023.103449","volume":"123","author":"P Bai","year":"2023","unstructured":"Bai, P. et al. The dual role of DNA repair protein MGMT in cancer prevention and treatment. DNA Repair. (Amst). 123, 103449 (2023).","journal-title":"DNA Repair. (Amst)"},{"issue":"2","key":"14731_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00280-020-04216-8","volume":"87","author":"C Lu","year":"2021","unstructured":"Lu, C., Li, X., Ren, Y. & Zhang, X. Disulfiram: a novel repurposed drug for cancer therapy. Cancer Chemother. Pharmacol. 87 (2), 159\u2013172 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"14","key":"14731_CR20","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.7150\/thno.98884","volume":"14","author":"M Chen","year":"2024","unstructured":"Chen, M. et al. Nanotechnology based gas delivery system: a green strategy for cancer diagnosis and treatment. Theranostics 14 (14), 5461\u20135491 (2024).","journal-title":"Theranostics"},{"key":"14731_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ph16081074","volume":"16","author":"V Aiassa","year":"2023","unstructured":"Aiassa, V., Garnero, C., Zoppi, A. & Longhi, M. R. Cyclodextrins and their derivatives as drug stability modifiers. Pharmaceuticals (Basel). 16, 8 (2023).","journal-title":"Pharmaceuticals (Basel)"},{"key":"14731_CR22","doi-asserted-by":"publisher","first-page":"41809","DOI":"10.1038\/srep41809","volume":"7","author":"M Jain","year":"2017","unstructured":"Jain, M. et al. Intravenous formulation of HET0016 decreased human glioblastoma growth and implicated survival benefit in rat xenograft models. Sci. Rep. 7, 41809 (2017).","journal-title":"Sci. Rep."},{"issue":"40","key":"14731_CR23","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.2174\/1381612823666171019164220","volume":"23","author":"P Calias","year":"2017","unstructured":"Calias, P. 2-Hydroxypropyl-\u03b2-cyclodextrins and the Blood-Brain barrier: considerations for Niemann-Pick disease type C1. Curr. Pharm. Des. 23 (40), 6231\u20136238 (2017).","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"14731_CR24","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1021\/acs.jcim.6b00215","volume":"56","author":"S Shityakov","year":"2016","unstructured":"Shityakov, S. et al. Characterization, in vivo evaluation, and molecular modeling of different Propofol-Cyclodextrin complexes to assess their drug delivery potential at the Blood-Brain barrier level. J. Chem. Inf. Model. 56 (10), 1914\u20131922 (2016).","journal-title":"J. Chem. Inf. Model."},{"issue":"27","key":"14731_CR25","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1021\/jm049568z","volume":"47","author":"D Cen","year":"2004","unstructured":"Cen, D., Brayton, D., Shahandeh, B., Meyskens, F. L. & Farmer, P. J. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J. Med. Chem. 47 (27), 6914\u20136920 (2004).","journal-title":"J. Med. Chem."},{"issue":"3","key":"14731_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3109\/10717544.2014.938839","volume":"23","author":"N Sharma","year":"2016","unstructured":"Sharma, N. & Baldi, A. Exploring versatile applications of cyclodextrins: an overview. Drug Deliv. 23 (3), 729\u2013747 (2016).","journal-title":"Drug Deliv."},{"issue":"3","key":"14731_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/1568026613666131127160118","volume":"14","author":"A Ottinger","year":"2014","unstructured":"Ottinger, A. et al. Collaborative development of 2-hydroxypropyl-\u03b2-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr. Top. Med. Chem. 14 (3), 330\u2013339 (2014).","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"14731_CR28","doi-asserted-by":"publisher","first-page":"41809","DOI":"10.1038\/srep41809","volume":"7","author":"M Jain","year":"2017","unstructured":"Jain, M. et al. Intravenous formulation of HET0016 decreased human glioblastoma growth and implicated survival benefit in rat xenograft models. Sci. Rep. 7 (1), 41809 (2017).","journal-title":"Sci. Rep."},{"issue":"4","key":"14731_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.18632\/oncotarget.27457","volume":"11","author":"FY Ling","year":"2020","unstructured":"Ling, F. Y. et al. Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. Oncotarget 11 (4), 443 (2020).","journal-title":"Oncotarget"},{"issue":"3","key":"14731_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neo.2014.03.006","volume":"16","author":"AD Berezovsky","year":"2014","unstructured":"Berezovsky, A. D. et al. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia 16 (3), 193\u2013206 (2014). e25.","journal-title":"Neoplasia"},{"issue":"12","key":"14731_CR31","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.7150\/thno.15898","volume":"6","author":"H Thisgaard","year":"2016","unstructured":"Thisgaard, H. et al. Highly effective auger-electron therapy in an orthotopic glioblastoma xenograft model using convection-enhanced delivery. Theranostics 6 (12), 2278 (2016).","journal-title":"Theranostics"},{"issue":"12","key":"14731_CR32","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2217\/nnm.12.92","volume":"7","author":"MM Ali","year":"2012","unstructured":"Ali, M. M. et al. A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma. Nanomedicine 7 (12), 1827\u20131837 (2012).","journal-title":"Nanomedicine"},{"issue":"6","key":"14731_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1593\/tlo.13559","volume":"6","author":"MM Ali","year":"2013","unstructured":"Ali, M. M. et al. Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. Translational Oncol. 6 (6), 660\u2013669 (2013).","journal-title":"Translational Oncol."},{"key":"14731_CR34","doi-asserted-by":"crossref","unstructured":"Ali, M. M. et al. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PloS One 5 (1), e8727. (2010).","DOI":"10.1371\/journal.pone.0008727"},{"key":"14731_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00280-020-04216-8","volume":"87","author":"C Lu","year":"2021","unstructured":"Lu, C., Li, X., Ren, Y. & Zhang, X. Disulfiram: a novel repurposed drug for cancer therapy. Cancer Chemother. Pharmacol. 87, 159\u2013172 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"14731_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2010.09.010","volume":"300","author":"F Wang","year":"2011","unstructured":"Wang, F. et al. A novel dithiocarbamate analogue with potentially decreased ALDH Inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells. Cancer Lett. 300 (1), 87\u201395 (2011).","journal-title":"Cancer Lett."},{"issue":"4","key":"14731_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.bbrc.2017.03.164","volume":"486","author":"YJ Kim","year":"2017","unstructured":"Kim, Y. J. et al. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. Biochem. Biophys. Res. Commun. 486 (4), 1069\u20131076 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"14731_CR38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1124\/mol.64.5.1076","volume":"64","author":"SG Shian","year":"2003","unstructured":"Shian, S. G., Kao, Y. R., Wu, F. Y. H. & Wu, C. W. Inhibition of invasion and angiogenesis by zinc-chelating agent Disulfiram. Mol. Pharmacol. 64 (5), 1076\u20131084 (2003).","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"14731_CR39","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.18632\/oncotarget.707","volume":"3","author":"P Hothi","year":"2012","unstructured":"Hothi, P. et al. High-throughput chemical screens identify Disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 3 (10), 1124 (2012).","journal-title":"Oncotarget"},{"issue":"12","key":"14731_CR40","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/CM9.0000000000002909","volume":"137","author":"M Zeng","year":"2024","unstructured":"Zeng, M. et al. Disulfiram: A novel repurposed drug for cancer therapy. Chin. Med. J. 137 (12), 1389\u20131398 (2024).","journal-title":"Chin. Med. J."},{"issue":"10","key":"14731_CR41","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1039\/C5AN00345H","volume":"140","author":"L Hakuna","year":"2015","unstructured":"Hakuna, L., Doughan, B., Escobedo, J. O. & Strongin, R. M. A simple assay for glutathione in whole blood. Analyst 140 (10), 3339\u20133342 (2015).","journal-title":"Analyst"},{"issue":"4","key":"14731_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ajhg.2014.03.007","volume":"94","author":"S Al Turki","year":"2014","unstructured":"Al Turki, S. et al. Rare variants in NR2F2 cause congenital heart defects in humans. Am. J. Hum. Genet. 94 (4), 574\u2013585 (2014).","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"14731_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2011.03.017","volume":"307","author":"M Lopus","year":"2011","unstructured":"Lopus, M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 307 (2), 113\u2013118 (2011).","journal-title":"Cancer Lett."},{"key":"14731_CR44","doi-asserted-by":"crossref","unstructured":"Bulcke, F., Dringen, R. & Scheiber, I. F. Neurotoxicity of copper. Neurotoxic. Met. 2017, 313\u2013343 .","DOI":"10.1007\/978-3-319-60189-2_16"},{"issue":"37","key":"14731_CR45","doi-asserted-by":"publisher","first-page":"10965","DOI":"10.1021\/bi034937z","volume":"42","author":"FP Guengerich","year":"2003","unstructured":"Guengerich, F. P., Fang, Q., Liu, L., Hachey, D. L. & Pegg, A. E. O 6-Alkylguanine-DNA alkyltransferase: low p K a and high reactivity of cysteine 145. Biochemistry 42 (37), 10965\u201310970 (2003).","journal-title":"Biochemistry"},{"issue":"3","key":"14731_CR46","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/carcin\/bgt366","volume":"35","author":"A Paranjpe","year":"2014","unstructured":"Paranjpe, A., Zhang, R., Ali-Osman, F., Bobustuc, G. C. & Srivenugopal, K. S. Disulfiram is a direct and potent inhibitor of human O 6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 35 (3), 692\u2013702 (2014).","journal-title":"Carcinogenesis"},{"issue":"1\u20132","key":"14731_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mrfmmm.2012.05.002","volume":"736","author":"P Georgiadis","year":"2012","unstructured":"Georgiadis, P., Polychronaki, N. & Kyrtopoulos, S. A. Progress in high-throughput assays of MGMT and APE1 activities in cell extracts. Mutat. Research\/Fundamental Mol. Mech. Mutagen. 736 (1\u20132), 25\u201332 (2012).","journal-title":"Mutat. Research\/Fundamental Mol. Mech. Mutagen."},{"issue":"6","key":"14731_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3727\/096504008786991611","volume":"17","author":"T Andrzejewski","year":"2008","unstructured":"Andrzejewski, T. et al. Therapeutic efficacy of curcumin\/trail combination regimen for hormone-refractory prostate cancer. Oncol. Res. 17 (6), 257\u2013267 (2008).","journal-title":"Oncol. Res."},{"issue":"5","key":"14731_CR49","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2486\/indhealth.MSWBVI-25","volume":"48","author":"A M-PRANESH","year":"2010","unstructured":"M-PRANESH, A., Rakheja, S. & Demont, R. Influence of support conditions on vertical whole-body vibration of the seated human body. Ind. Health. 48 (5), 682\u2013697 (2010).","journal-title":"Ind. Health"},{"issue":"4","key":"14731_CR50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3390\/biomedicines11041081","volume":"11","author":"K Almeida Lima","year":"2023","unstructured":"Almeida Lima, K. et al. Temozolomide resistance in glioblastoma by NRF2: protecting the evil. Biomedicines 11 (4), 1081 (2023).","journal-title":"Biomedicines"},{"key":"14731_CR51","doi-asserted-by":"publisher","first-page":"115730","DOI":"10.1016\/j.biopha.2023.115730","volume":"168","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Copper-mediated novel cell death pathway in tumor cells and implications for innovative cancer therapies. Biomed. Pharmacother. 168, 115730 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"14731_CR52","doi-asserted-by":"publisher","first-page":"103449","DOI":"10.1016\/j.dnarep.2023.103449","volume":"123","author":"P Bai","year":"2023","unstructured":"Bai, P. et al. The dual role of DNA repair protein MGMT in cancer prevention and treatment. DNA Repair. 123, 103449 (2023).","journal-title":"DNA Repair."},{"issue":"2","key":"14731_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/stem.264","volume":"28","author":"AC DeCarvalho","year":"2010","unstructured":"DeCarvalho, A. C. et al. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells. 28 (2), 181\u2013190 (2010).","journal-title":"Stem Cells"},{"issue":"6","key":"14731_CR54","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3390\/pharmaceutics15061567","volume":"15","author":"X Kang","year":"2023","unstructured":"Kang, X. et al. Advancing cancer therapy with copper\/disulfiram nanomedicines and drug delivery systems. Pharmaceutics 15 (6), 1567 (2023).","journal-title":"Pharmaceutics"},{"key":"14731_CR55","doi-asserted-by":"publisher","first-page":"933655","DOI":"10.3389\/fphar.2022.933655","volume":"13","author":"S Zhong","year":"2022","unstructured":"Zhong, S. et al. Disulfiram in glioma: literature review of drug repurposing. Front. Pharmacol. 13, 933655 (2022).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"14731_CR56","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/10717544.2019.1616235","volume":"26","author":"D Wang","year":"2019","unstructured":"Wang, D., Wang, C., Wang, L. & Chen, Y. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain\/brain tumor barriers for glioblastoma treatment. Drug Deliv. 26 (1), 551\u2013565 (2019).","journal-title":"Drug Deliv."},{"issue":"11","key":"14731_CR57","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.3390\/curroncol30110702","volume":"30","author":"A Gozdz","year":"2023","unstructured":"Gozdz, A. Proteasome inhibitors against Glioblastoma\u2014Overview of molecular mechanisms of cytotoxicity, progress in clinical trials, and perspective for use in personalized medicine. Curr. Oncol. 30 (11), 9676\u20139688 (2023).","journal-title":"Curr. Oncol."},{"issue":"6","key":"14731_CR58","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/neuonc\/noab003","volume":"23","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. A., PARP-mediated parylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro-oncology 23 (6), 920\u2013931 (2021).","journal-title":"Neuro-oncology"},{"issue":"2","key":"14731_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1523\/JNEUROSCI.0933-21.2021","volume":"42","author":"DA Becktel","year":"2022","unstructured":"Becktel, D. A. et al. Repeated administration of 2-hydroxypropyl-\u03b2-cyclodextrin (HP\u03b2CD) attenuates the chronic inflammatory response to experimental stroke. J. Neurosci. 42 (2), 325\u2013348 (2022).","journal-title":"J. Neurosci."},{"issue":"8","key":"14731_CR60","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","volume":"35","author":"R Kamaraj","year":"2024","unstructured":"Kamaraj, R. et al. Targeted protein degradation (TPD) for immunotherapy: Understanding proteolysis targeting Chimera-Driven Ubiquitin-Proteasome interactions. Bioconjug. Chem. 35 (8), 1089\u20131115 (2024).","journal-title":"Bioconjug. Chem."},{"issue":"72","key":"14731_CR61","doi-asserted-by":"publisher","first-page":"33623","DOI":"10.18632\/oncotarget.25890","volume":"9","author":"K Hafazalla","year":"2018","unstructured":"Hafazalla, K., Sahgal, A., Jaja, B., Perry, J. R. & Das, S. Procarbazine, CCNU and vincristine (PCV) versus Temozolomide chemotherapy for patients with low-grade glioma: a systematic review. Oncotarget 9 (72), 33623 (2018).","journal-title":"Oncotarget"},{"key":"14731_CR62","doi-asserted-by":"crossref","unstructured":"Sandbhor, P., Palkar, P., Bhat, S., John, G. & Goda, J. S. Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy. Nanoscale 16, 6330\u20136364 (2024).","DOI":"10.1039\/D3NR06131K"},{"issue":"5","key":"14731_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","volume":"24","author":"KH Narsinh","year":"2024","unstructured":"Narsinh, K. H. et al. Strategies to improve drug delivery across the Blood\u2013Brain barrier for glioblastoma. Curr. Neurol. Neurosci. Rep. 24 (5), 123\u2013139 (2024).","journal-title":"Curr. Neurol. Neurosci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14731-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:05:02Z","timestamp":1758809102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14731-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14731"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14731-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. Henry Ford Health has received travel compensation on behalf of JMS for presentations not related to this work by Hoffmann-La Roche AG and Premier Applied Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32869"}}